Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof

Abstract

There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.

1 - 13 . (canceled) 
   
   
       14 . A method for preventing recurrence of cerebrovascular disorder in a mammal, which comprises administering an effective amount of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof to the mammal, provided that the compound having an angiotension II antagonistic activity is not a compound represented by formula (I): 
     
       
         
         
             
             
         
       
     
     wherein R 1  represents a group capable of forming an anion or being converted into said group, X indicates that the phenylene group and the phenyl group are bound to each other directly or via a spacer of a chain made of 2 or less atoms, n is an integer of 1 or 2, ring A represents a benzene ring which may further have substituent(s), R 2  represents a group capable of forming an anion or being converted into said group, and R 3  represents a hydrocarbon residue which may be bound via a heteroatom and may have substituent(s). 
   
   
       15 . A method for ameliorating troubles following cerebrovascular disorder or inhibiting progress thereof in a mammal, which comprises administering an effective amount of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof to the mammal. 
   
   
       16 - 17 . (canceled) 
   
   
       18 . The method according to  claim 14 , wherein the compound having an angiotensin II antagonistic activity is a non-peptide compound. 
   
   
       19 . The method according to  claim 14 , wherein the compound having an angiotensin II antagonistic activity is a compound having an oxygen atom in the molecule. 
   
   
       20 . The method according to  claim 14 , wherein the compound having an angiotensin II antagonistic activity is a compound having an ether bond or a carbonyl group. 
   
   
       21 . The method according to  claim 14 , wherein the compound having an angiotensin II antagonistic activity is Losartan, Eprosartan, Valsartan, Telmisartan, Irbesartan, Olmesartan or Tasosartan. 
   
   
       22 . The method according to  claim 14 , wherein the cerebrovascular disorder caused nerve symptoms. 
   
   
       23 . The method according to  claim 14 , wherein the cerebrovascular disorder caused mental symptoms. 
   
   
       24 . The method according to  claim 14 , wherein the cerebrovascular disorder caused subjective symptoms. 
   
   
       25 . The method according to  claim 14 , wherein the cerebrovascular disorder caused obstacles in activities of daily living. 
   
   
       26 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is a non-peptide compound. 
   
   
       27 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is a compound having an oxygen atom in the molecule. 
   
   
       28 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is a compound having an ether bond or a carbonyl group. 
   
   
       29 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is a compound represented by the formula (I): 
     
       
         
         
             
             
         
       
     
     wherein R 1  represents a group capable of forming an anion or being converted into said group, X indicates that the phenylene group and the phenyl group are bound to each other directly or via a spacer of a chain made of 2 or less atoms, n is an integer of 1 or 2, ring A represents a benzene ring which may further have substituent(s), R 2  represents a group capable of forming an anion or being converted into said group, and R 3  represents a hydrocarbon residue which may be bound via a heteroatom and may have substituent(s). 
   
   
       30 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is Losartan, Eprosartan, Candesartan cilexetil, Candesartan, Valsartan, Telmisartan, Irbesartan, Olmesartan or Tasosartan. 
   
   
       31 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid. 
   
   
       32 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate. 
   
   
       33 . The method according to  claim 15 , wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid. 
   
   
       34 . The method according to  claim 15 , wherein the troubles following cerebrovascular disorder are nerve symptoms. 
   
   
       35 . The method according to  claim 15 , wherein the troubles following cerebrovascular disorder are mental symptoms. 
   
   
       36 . The method according to  claim 15 , wherein the troubles following cerebrovascular disorder are subjective symptoms. 
   
   
       37 . The method according to  claim 15 , wherein the troubles following cerebrovascular disorder are obstacles in activities of daily living.